ReviewCurrent gastroenterology reports2006
Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned.
Review in Current gastroenterology reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 37 citations in OpenAlex.
- Prospective study on the impact of BEAM versus FEAM conditioning on occurrence of neutropenic enterocolitis and on transplant outcome in lymphoma patients.Frontiers in oncology · 2024Article
- Impact of different chemotherapy regimens on intestinal mucosal injury assessed with bedside ultrasound: a study in 213 AML patients.Frontiers in oncology · 2023Article
- Abdominal pain and fever in a patient with human immunodeficiency virus: a case report.International journal of emergency medicine · 2022Article
- International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.Ecancermedicalscience · 2022Article
- Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective Study.Journal of clinical medicine · 2021Article
- Neutropenic enterocolitis in pediatric leukemia patients treated with intensive chemotherapy in Upper Egypt.Pediatric investigation · 2020Article
- Complications of systemic therapy--gut infections and acute diarrhoea.Clinical medicine (London, England) · 2014Article
- Presentation and management of docetaxel-related adverse effects in patients with breast cancer.Cancer management and research · 2014Review
- Colorectal cancer emergencies.Journal of gastrointestinal cancer · 2013Review
- Passage of intestinal (small bowel) cast--an unusual complication of neutropenic sepsis.BMJ case reports · 2010Article
- Meibomian gland changes in breast cancer patients treated with docetaxel-partial results.Romanian journal of ophthalmologyArticle
- Neutropenic Enterocolitis in the Treatment of Solid Tumors: A Case Report and Review of the Literature.Case reports in oncologyArticle
- Neutropenic Enterocolitis in Acute Myeloid Leukemia and Morbus Behcet: Pivotal Role of Medical Imaging and Multidisciplinary Management in a Complex Clinical Case.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neutropenic enterocolitis (NE) must be recognized in patients with fever, neutropenia, and abdominal pain. Classically, NE has been described in patients with hematologic malignancies treated with intensive chemotherapy. Current interest in NE has increased due to recent cases associated with newer, more intensive chemotherapy in solid tumors. This review discusses pathology, clinical presentation, and treatment of NE. Ultrasonography or CT scans are the best radiographic studies to confirm the diagnosis. Management options, including antimicrobial therapy, surgery, and supportive care, are discussed. Chemotherapy incorporating the taxane family of drugs (paclitaxel and docetaxel) associated with NE is also reviewed with observations regarding the earlier onset of the disease in the first weeks following chemotherapy. Even with currently recommended therapy, a high mortality rate, approximating 45%, can occur. Best outcomes for NE rely upon understanding of risks for the condition, prompt empiric therapy with broad-spectrum antimicrobial agents, systemic antifungal therapy, and meticulous attention to supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.